# The Design, Synthesis, and Evaluation of the Biological Activity of Hydroxamic Derivatives of Sorafenib

## TL;DR

This paper describes the design and testing of new sorafenib derivatives that may better inhibit cancer cell growth.

## Contribution

The study introduces novel hydroxamic derivatives of sorafenib with deacetylase-inhibiting properties.

## Key findings

- The synthesized derivatives showed cancer cell proliferation suppression.
- The effectiveness of the derivatives depends on the structure of the deacetylase element.

## Abstract

Sorafenib is a multiple tyrosine kinase inhibitor that is used in the treatment
of liver and renal cancers. We synthesized the hydroxamic derivatives of
sorafenib bearing the pharmacophore elements of zinc-dependent histone
deacetylase inhibitors. We uncovered that suppression of cancer cell
proliferation by the synthesized hybrid inhibitors critically depends on the
structure of the “deacetylase” element.